New list of reimbursed drugs from October 1, 2026

The new list of reimbursed drugs will come into force on October 1, 2026. Deputy Minister of Health Katarzyna Kacperczyk assures that the list includes therapies that meet the needs of patients with the most serious diseases.

Substances covered by reimbursement concern primarily rheumatoid diseases, but the list also includes hormone replacement therapies and endometriosis treatment - Kacperczyk enumerated at last week's press conference.

The new drugs include, among others: adalimumab (for rheumatoid arthritis), selexipag (for pulmonary arterial hypertension) and antidepressants. The reimbursement will cover 18 new molecular indications and the extension of existing indications for six further therapies.

Priority: oncology and rare diseases

The latest list includes, among others: new therapies for patients with lung, stomach, esophagus and colon cancer. Combination therapy with pembrolizumab and axitinib has been introduced in kidney cancer, and encorafenic and cetuximab in the treatment of stomach, esophagus and colon cancer.

Another important novelty is the reimbursement of the first drug for Duchenne muscular dystrophy (vamorolone), higher dosage of nusinersen in SMA and new therapeutic options for patients with cystic fibrosis.

For the first time, targeted therapy for von Hippel-Lindau syndrome - a rare genetic disease that increases the risk of developing numerous tumors - was reimbursed.

This year, we covered 90 new therapies, including 46 oncology therapies, summed up Katarzyna Kacperczyk.

Which medicines are getting more expensive and which are getting cheaper?

Patients will pay less for 312 drugs - from a symbolic penny to as much as PLN 212.80 per package. The discounts will include, among others: drugs with rivaroxaban (for thrombosis and pulmonary embolism), follitropin delta (for infertility) and denosumab (for osteoporosis).